BMJ 2000;321:3-4 ( 1 July )

Editorials

The argument against sentinel node biopsy for malignant melanoma

Its use should be confined to patients in clinical trials

The first 150 words of the full text of this article appear below.

Sentinel node biopsy has been enthusiastically adopted into clinical practice without a clear understanding of its benefit, which is often assumed rather than proved. Recently, the status of the sentinel node has been shown to be the most important predictor of recurrence and survival for patients with malignant melanoma. The proportion of patients who have had a negative sentinel node biopsy and who are free of disease at three years is 88.5% compared with 55.8% of patients with a positive biopsy; these groups have overall survival rates of 93% and 67%, respectively. ^{1 2}

The thickness of the tumour and whether there is ulceration remain important prognostic discriminators in patients with a negative biopsy.¹ But is the ability to stratify patients prognostically enough to justify the widespread use of sentinel node biopsy or should we wait for evidence of a survival benefit after selective node dissection in patients who have had a . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Completion lymphadenectomy may not increase in-transit disease in malignant melanoma

Robin Russell-Jones, Ciaran Healy, Ann-Marie Powell, Katharine Acland, Michael O'Doherty, and Eduardo Calonje
BMJ 2004 329: 1288-1289. [Extract] [Full Text]

Sentinel node biopsy for malignant melanoma

S S Rayatt, S P Hettiaratchy, Sarah Wookey, Barry Powell, M Dalvi Humzah, Robin Russell-Jones, Eduardo Calonje, Ciaran Healy, Michael Doherty, Peter Butler, Alison Jones, Sean Whittaker, Katharine Acland, J Meirion Thomas, and Erica J Patocskai
BMJ 2000 321: 1285. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Johnson, D, Whitworth, I H (2002). Recent developments in plastic surgery. BMJ 325: 319-322 [Full text]  
• Lens, M. B., Dawes, M., Goodacre, T., Newton-Bishop, J. A. (2002). Elective Lymph Node Dissection in Patients With Melanoma: Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Surg 137: 458-461 [Abstract] [Full text]  
• McMasters, K. M., Reintgen, D. S., Ross, M. I., Gershenwald, J. E., Edwards, M. J., Sober, A., Fenske, N., Glass, F., Balch, C. M., Coit, D. G. (2001). Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement. JCO 19: 2851-2855 [Abstract] [Full text]  
• Rayatt, S S, Hettiaratchy, S P, Wookey, S., Powell, B., Humzah, M D., Russell-Jones, R., Calonje, E., Healy, C., Doherty, M., Butler, P., Jones, A., Whittaker, S., Acland, K., Thomas, J M., Patocskai, E. J (2000). Sentinel node biopsy for malignant melanoma. BMJ 321: 1285-1285 [Full text]  

Rapid Responses:

Read all Rapid Responses

What is a prognosis worth?

Sarah Wookey
bmj.com, 2 Jul 2000 [Full text]

Sentinel Lymph Node Biopsy: Cost Implications & the Oxford Experience

David Lam
bmj.com, 2 Jul 2000 [Full text]

Sentinel Node Biopsy for Staging and Prognosis

M Dalvi Humzah
bmj.com, 12 Jul 2000 [Full text]

Psychological benefits of sentinel lymph node biopsy

Sukh Rayatt
bmj.com, 24 Jul 2000 [Full text]

No UK trials are currently recruiting, but future ones deserve support

Barry Powell
bmj.com, 19 Jul 2000 [Full text]

The argument for sentinel node biopsy

Robin Russell-Jones
bmj.com, 14 Aug 2000 [Full text]

Sentinel Node Biopsy

Paul E Baguley
bmj.com, 29 Aug 2000 [Full text]

Online poll

Find out more>>